{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:22:07Z","timestamp":1761740527532,"version":"3.40.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T00:00:00Z","timestamp":1417737600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12328-014-0545-8","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T07:01:13Z","timestamp":1417676473000},"page":"47-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites"],"prefix":"10.1007","volume":"8","author":[{"given":"Atsushi","family":"Goto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munetaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,5]]},"reference":[{"key":"545_CR1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, et\u00a0al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"545_CR2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, et\u00a0al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u2013112.","journal-title":"N Engl J Med"},{"key":"545_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","volume":"25","author":"T Miyazaki","year":"2007","unstructured":"Miyazaki T, Fujiki H, Yamamura Y, et\u00a0al. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist\u2014pharmacology and clinical trials. Cardiovasc Drug Rev. 2007;25:1\u201313.","journal-title":"Cardiovasc Drug Rev"},{"key":"545_CR4","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","volume":"25","author":"M Matsuzaki","year":"2011","unstructured":"Matsuzaki M, Hori M, Izumi T, et\u00a0al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25:S33\u201345.","journal-title":"Cardiovasc Drugs Ther"},{"key":"545_CR5","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, et\u00a0al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332\u201343.","journal-title":"JAMA"},{"key":"545_CR6","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1365-2036.2006.03088.x","volume":"24","author":"PJ Thuluvath","year":"2006","unstructured":"Thuluvath PJ, Maheshwari A, Wong F, et\u00a0al. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. Aliment Pharmacol Ther. 2006;24:973\u201382.","journal-title":"Aliment Pharmacol Ther"},{"key":"545_CR7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hepr.12099","volume":"44","author":"K Okita","year":"2014","unstructured":"Okita K, Kawazoe S, Hasebe C, et\u00a0al. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:83\u201391.","journal-title":"Hepatol Res"},{"key":"545_CR8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/hepr.12171","volume":"44","author":"I Sakaida","year":"2013","unstructured":"Sakaida I, Okita K. Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy. Hepatol Res. 2013;44:735\u20139.","journal-title":"Hepatol Res"},{"key":"545_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","volume":"44","author":"I Sakaida","year":"2014","unstructured":"Sakaida I, Kawazoe S, Kajimura K, et\u00a0al. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73\u201382.","journal-title":"Hepatol Res"},{"key":"545_CR10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1536\/ihj.54.377","volume":"54","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Minatsuki S, et\u00a0al. Tolvaptan can improve clinical course in responders. Int Heart J. 2013;54:377\u201381.","journal-title":"Int Heart J"},{"key":"545_CR11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1253\/circj.CJ-12-0971","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Shiga T, et\u00a0al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients\u2014association between non-responders and chronic kidney disease. Circ J. 2013;77:397\u2013404.","journal-title":"Circ J"},{"key":"545_CR12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1253\/circj.CJ-12-1328","volume":"77","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Minatsuki S, et\u00a0al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J. 2013;77:1208\u201313.","journal-title":"Circ J"},{"key":"545_CR13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1253\/circj.CJ-12-1535","volume":"77","author":"K Dohi","year":"2013","unstructured":"Dohi K, Watanabe K, Ito M. Urine osmolality-guided tolvaptan therapy in decompensated heart failure. Circ J. 2013;77:313\u20134.","journal-title":"Circ J"},{"key":"545_CR14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00041552-199801000-00007","volume":"7","author":"PM Deen","year":"1998","unstructured":"Deen PM, Knoers NV. Physiology and pathophysiology of the aquaporin-2 water channel. Curr Opin Nephrol Hypertens. 1998;7:37\u201342.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"545_CR15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1536\/ihj.54.115","volume":"54","author":"T Imamura","year":"2013","unstructured":"Imamura T, Kinugawa K, Kato N, et\u00a0al. A case with recovery of response to tolvaptan associated with remission of acute kidney injury and increased urine osmolality. Int Heart J. 2013;54:115\u20138.","journal-title":"Int Heart J"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-014-0545-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-014-0545-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-014-0545-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:57:23Z","timestamp":1747177043000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-014-0545-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1007\/s12328-014-0545-8","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}